-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Factor XI as a Therapeutic Target

Program: Spotlight Sessions
Session: Factor XI - From Bleeding to Thrombosis
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Translational Research, drug development, Diseases, Therapies
Monday, December 11, 2023, 2:45 PM-4:00 PM

David Gailani, MD

Vanderbilt University, Nashville, TN

Disclosures: Gailani: Anthos Therapetuics: Consultancy, Honoraria; Aronora: Consultancy, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties: Factor XI and factor XII inhibitors; Bristol-Myers Squibb: Consultancy, Honoraria; Ionis: Consultancy, Honoraria; Janssen: Consultancy, Honoraria.

Previous Presentation | Next Presentation >>